2. Tajar A., Huhtaniemi I.T., O’Neill T.W. et al. Characteristics of androgen deficiency in late-onset hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012; 97(5): 1508–16. https://dx.doi.org/10.1210/jc.2011-2513.

3. Barbonetti A., D’Andrea S., Francavilla S. Testosterone replacement therapy. Andrology. 2020; 8(6): 1551–66.https://dx.doi.org/10.1111/andr.12774.

4. Corona G., Torres L.O., Maggi M. Testosterone therapy: What we have learned from trials. J Sex Med. 2020; 17(3): 447–60.https://dx.doi.org/10.1016/j.jsxm.2019.11.270.

5. Mulhall J.P., Trost L.W., Brannigan R.E. et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018; 200(2): 423–32. https://dx.doi.org/10.1016/j.juro.2018.03.115.

6. Hackett G., Kirby M., Edwards D. et al. British society for sexual medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med. 2017; 14(12): 1504–23. https://dx.doi.org/10.1016/j.jsxm.2017.10.067.

7. Morales A., Bebb R.A., Manjoo P. et al. Diagnosis and management of testosterone deficiency syndrome in men: Clinical practice guideline. CMAJ. 2015; 187(18): 1369–77. https://dx.doi.org/10.1503/cmaj.150033.

8. Bhasin S., Brito J.P., Cunningham G.R. et al. Testosterone therapy in men with hypogonadism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018; 103(5): 1715–44. https://dx.doi.org/10.1210/jc.2018-00229.

9. Yeap B.B., Grossmann M., McLachlan R.I. et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): Assessment and indications for testosterone therapy. Med J Aust. 2016; 205(4): 173–78. https://dx.doi.org/10.5694/mja16.00393.

10. Yeap B.B., Grossmann M., McLachlan R.I. et al. Endocrine Society of Australia position statement on male hypogonadism (part 2): Treatment and therapeutic considerations. Med J Aust. 2016; 205(5): 228–31. https://dx.doi.org/10.5694/mja16.00448.

11. Corona G., Goulis D.G., Huhtaniemi I. et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology. Andrology. 2020; 8(5): 970–87. https://dx.doi.org/10.1111/andr.12770.

12. Salonia A., Bettocchi C., Boeri L. et al.; EAU Working Group on Male Sexual and Reproductive Health. European Association of Urology guidelines on sexual and reproductive health-2021 update: Male sexual dysfunction. Eur Urol. 2021; 80(3): 333–57.https://dx.doi.org/10.1016/j.eururo.2021.06.007.

13. Morgentaler A., Traish A., Hackett G. et al. Diagnosis and treatment of testosterone deficiency: updated recommendations from the Lisbon 2018 international consultation for sexual medicine. Sex Med Rev. 2019; 7(4): 636–49.https://dx.doi.org/10.1016/j.sxmr.2019.06.003.

14. Lunenfeld B., Mskhalaya G., Zitzmann M. et al. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021; 24(1): 119–38. https://dx.doi.org/10.1080/13685538.2021.1962840.

15. Qaseem A., Horwitch C.A., Vijan S. et al. Clinical guidelines committee of the american college of physicians. Testosterone treatment in adult men with age-related low testosterone: A clinical guideline from the American College of Physicians. Ann Intern Med. 2020; 172(2): 126–33. https://dx.doi.org/10.7326/M19-0882.

16. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Роживанов Р.В. с соавт. Проект клинических рекомендаций «Синдром гипогонадизма у мужчин». Ожирение и метаболизм. 2021; 18(4): 496–507. [Dedov I.I., Mokrysheva N.G., Melnichenko G.A., Rozhivanov R.V. et al. Draft of Russian clinical practice guidelines «Male hypogonadism». Ozhirenie i metabolism = Obesity and metabolism. 2021; 18(4): 496–507 (In Russ.)]. https://dx.doi.org/10.14341/omet12817. EDN: FUWRTV.

17. Wu F.C.W., Tajar A., Beynon J.M. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010; 363(2): 123–35. https://dx.doi.org/10.1056/NEJMoa0911101.

18. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск (дополненный). Сахарный диабет. 2021; 24(1S): 1–148. (Standards of specialized diabetes care. Ed. by Dedov I.I., Shestakova M.V., Mayorov A.Yu. Sakharny diabet = Diabetes Mellitus. 2021; 24(1S): 1–148 (In Russ.)]. https://dx.doi.org/10.14341/DM12802. EDN: ISOZCM.

19. Zitzmann M., Faber S., Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006; 91(11): 4335–43. https://dx.doi.org/10.1210/jc.2006-0401.

20. Heinemann L.A.J., Zimmermann T., Vermeulen A. et al. A new «aging males» symptoms’ rating scale. Aging Male. 1999; 2: 105–14. https://dx.doi.org/10.3109/13685539909003173.

21. Morley J.E., Charlton E., Patrick P. et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000; 49(9): 1239–42. https://dx.doi.org/10.1053/meta.2000.8625.

22. Smith K.W., Feldman H.A., McKinlay J.B. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf). 2000; 53(6): 703–11. https://dx.doi.org/10.1046/j.1365-2265.2000.01152.x.

23. Corona G., Mannucci E., Petrone L. et al. ANDROTEST: A structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med. 2006; 3(4): 706–15. https://dx.doi.org/10.1111/j.1743-6109.2006.00262.x.

24. Tajar A., Forti G., O’Neill T.W. et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010; 95(4): 1810–18. https://dx.doi.org/10.1210/jc.2009-1796.

25. Vesper H.W., Bhasin S., Wang C. et al. Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids. 2009; 74(6): 498–503. https://dx.doi.org/10.1016/j.steroids.2009.01.004.

26. Huhtaniemi I.T., Tajar A., Lee D.M. et al. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol. 2012; 166(6): 983–91. https://dx.doi.org/10.1530/EJE-11-1051.

27. Free & Bioavailable Testosterone calculator. URL: http://www.issam.ch/freetesto.htm (date of access – 01.11.2022).

28. Rastrelli G., Corona G., Maggi M. Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction. Asian J Androl. 2020; 22(3): 265–73. https://dx.doi.org/10.4103/aja.aja_61_19.

29. Fiers T., Wu F., Moghetti P. et al. Reassessing free-testosterone calculation by liquid chromatography-tandem mass spectrometry direct equilibrium dialysis. J Clin Endocrinol Metab. 2018; 103(6): 2167–74. https://dx.doi.org/10.1210/jc.2017-02360.

30. Guay A., Miller M.G., McWhirter C.L. Does early morning versus late morning draw time influence apparent testosterone concentration in men aged > or = 45 years? Data from the Hypogonadism In Males study. Int J Impot Res. 2008; 20(2): 162–67.https://dx.doi.org/10.1038/sj.ijir.3901580.

31. Snyder P.J., Bhasin S., Cunningham G.R. et al. Lessons from the testosterone trials. Endocr Rev. 2018; 39(3): 369–86.https://dx.doi.org/10.1056/NEJMoa1506119.

32. Giagulli V.A., Triggiani V., Corona G. et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: Focus on new formulations. Curr Pharm Des. 2011; 17(15): 1500–11.https://dx.doi.org/10.1111/j.1743-6109.2011.02497.x.

33. Grossmann M., Matsumoto A.M. A perspective on middle-aged and older men with functional hypogonadism: Focus on holistic management. J Clin Endocrinol Metab. 2017; 102(3): 1067–75. https://dx.doi.org/10.1210/jc.2016-3580.

34. Corona G., Rastrelli G., Morelli A. et al. Treatment of functional hypogonadism besides pharmacological substitution. World J Men’s Health. 2020; 38(3): 256. https://dx.doi.org/10.1016/j.jsxm.2018.04.641.

35. Cignarelli A., Castellana M., Castellana G. et al. Effects of CPAP on testosterone levels in patients with obstructive sleep apnea: A meta-analysis study. Front Endocrinol (Lausanne). 2019; 10: 551. https://dx.doi.org/10.3389/fendo.2019.00551.

36. Giagulli V.A., Castellana M., Murro I. et al. The role of diet and weight loss in improving secondary hypogonadism in men with obesity with or without type 2 diabetes mellitus. Nutrients. 2019; 11(12): 2975. https://dx.doi.org/10.3390/nu11122975.

37. Bray G.A., Heisel W.E., Afshin A. et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018; 39(2): 79–132. https://dx.doi.org/10.1210/er.2017-00253.

38. Wing R.R., Rosen R.C., Fava J.L. et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 2010; 7(1 Pt 1): 156–65. https://dx.doi.org/10.1111/j.1743-6109.2009.01458.x.

39. Pelusi C., Giagulli V.A., Baccini M. et al. Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study. PLoS One. 2017; 12(9): e0183369.https://dx.doi.org/10.1371/journal.pone.0183369.

40. Krzastek S.C., Smith R.P. Non-testosterone management of male hypogonadism: an examination of the existing literature. Transl Androl Urol. 2020; 9(Suppl 2): S160–S170. https://dx.doi.org/10.21037/tau.2019.11.16.

41. Rastrelli G., Maggi M., Corona G. Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol. 2018; 11(4): 439–58. https://dx.doi.org/10.1080/17512433.2018.1445969.

42. Giagulli V.A., Castellana M., Lisco G., Triggiani V. Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology. 2020; 8(6): 1628–41. https://dx.doi.org/10.1111/andr.12850.